MESO:NASDAQ; MSB:ASE; MBLTY:OTCPK

Mesoblast Ltd.

Mesoblast Ltd. is a clinical development company leveraging its proprietary core adult stem cell technologies, which include the Mesenchymal Precursor Cell (MPC) and culture-expanded Mesenchymal Stem Cell (MSC) platform technologies, Dental Pulp Stem Cells and expanded Hematopoietic Stem Cells. The company's cardiovascular and neurologic product pipeline is being developed in partnership with Teva Pharmaceutical Industries Ltd. Mesoblast Ltd's subsidiaries include Mesoblast Inc., Mesoblast International SA, Mesoblast Australia Pty Ltd and Mesoblast UK Ltd.
MESO:NASDAQ MSB:ASE

Expert Comments:

Dennis Hulme, Edison Investment Research (5/11/16)
"In its Q3 FY16 results presentation Mesoblast revealed the Phase III trial of Revascor in CHF cleared its first interim safety analysis. . .Mesoblast and Teva will update the market on timelines for the CHF Phase III programme later this quarter, while RA and GvHD data are expected next quarter. Mesoblast maintained a reduced cash burn of US$22m in Q3, giving it a cash runway to end FY17 on our estimates. . .our valuation is unchanged at A$7.36 per share ahead of the CHF programme update."

Kevin DeGeeter, Ladenburg Thalmann (5/10/16)
"Mesoblast Ltd. announced 3Q16 results in line with our forecast and provided several important updates including: 1) agreement with FDA regarding Phase III study design for its MPC-06-ID program for treatment of chronic lower back pain, 2) confirmation of positive interim review by the DSMB for the Phase III heart failure program, and 3) positive enrollment update on U.S. pediatric GvHD Phase III program with potential interim results late in 3Q16. . .the company is now well positioned to potentially conclude partnering discussions for MPC-06-ID in the coming months. . .we reiterate our Buy rating and $17.25 price target."

Jason Kolbert, Maxim Group (5/10/16)
"Mesoblast Ltd. spent $22M in the quarter and closed the period with $100M in cash. . .the company highlighted the lower cash burn, down 25% vs. the same period last year. . .the heart failure trial is recruiting well in North America and is expected to expand more aggressively in the EU, as sites there are being opened."

Katherine Genis, Edison Investment Research (3/24/16)
"In September 2015 Mesoblast Ltd. announced Phase 2 trial results for MPC-150-IM, showing greatest cardioprotective effect in patients with advanced heart failure. Clinical data from two Phase 3 studies will support regulatory approval; interim analysis of the first trial is anticipated in Q2/16."

Jason Kolbert, Maxim Group (3/17/16)
"The strength in Mesoblast Ltd.'s shares appears to be a result of an artificially depressed valuation triggered by the U.S. NASDAQ listing. Given the success in Japan and the multiple catalysts ahead, as well as other recent success in the competitive landscape of cell therapy, we believe the rebound in valuation is justified."

Henry McCusker, RegMed Investors (2/25/16)
"A Mesoblast Ltd. licensee launched the first allogeneic cell therapy product in Japan for the treatment of acute graft-versus-host disease in children and adults. . .Temcell is the first allogeneic cell therapy to be fully approved in Japan. The Japanese government's National Health Insurance set reimbursement for Temcell at 868,680 yen (approximately $7,700) per bag of 72M cells."

More Expert Comments

Experts Following This Company

Kevin DeGeeter, Director, Equity Research Analyst – Ladenburg Thalmann
Katherine Genis, Analyst – Edison Investment Research
Dennis Hulme, Analyst – Edison Investment Research
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Henry McCusker, Founder and Director of Research – Scimitar Equity
Henry McCusker RegMed Investors
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters, the company and other contributors.

Mesoblast Ltd. is a former billboard advertiser of Streetwise Reports. The company's advertising fees paid for Streetwise Reports to create this "Investor Summary Page," to which links were placed on Streetwise Reports' websites and newsletters. Streetwise Reports did not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.